Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $7.96, but opened at $8.20. Abivax shares last traded at $8.02, with a volume of 70,080 shares traded.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $33.00 price target on shares of Abivax in a research note on Wednesday, April 30th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 target price on shares of Abivax in a research report on Thursday, March 20th.
View Our Latest Stock Analysis on ABVX
Abivax Price Performance
The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25. The company's 50-day moving average is $6.77 and its 200 day moving average is $6.70.
Institutional Investors Weigh In On Abivax
Hedge funds have recently bought and sold shares of the business. Octagon Capital Advisors LP purchased a new stake in shares of Abivax in the first quarter worth approximately $7,688,000. ADAR1 Capital Management LLC lifted its position in Abivax by 190.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company's stock worth $11,078,000 after buying an additional 991,781 shares in the last quarter. Caligan Partners LP purchased a new stake in Abivax in the 4th quarter worth approximately $5,506,000. JPMorgan Chase & Co. purchased a new stake in Abivax in the 4th quarter worth approximately $5,336,000. Finally, Allostery Investments LP purchased a new stake in shares of Abivax during the fourth quarter worth $4,328,000. 47.91% of the stock is owned by hedge funds and other institutional investors.
Abivax Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
